Without rigorous design and strategic planning, psychiatry research walks a fine line between hard science and subjectivity. That’s why Worldwide designs studies that balance the needs of stakeholders at every stage of the process.
By developing close working relationships with key clinical leaders and engaging a broad network of clinicians globally, Worldwide fosters improved participation and quality for psychiatry clinical trials. To go a step further by also appealing to patients and regulators, you need a dedicated team with experience navigating a narrow road—a team that speaks a language everyone understands, and designs and executes a study that balances everyone’s priorities.
Worldwide has a proven track record and wealth of experience within our therapeutically aligned team. Our clinicians, scientists, staff and project teams have extensive experience in conducting all phases of clinical trials with more than 50 psychiatry studies enrolling over 7,000 patients globally.
Senior Vice President, Medical Sciences
Bartosz Janikowski, MD, Senior Vice President, Medical Sciences at Worldwide Clinical Trials, is a board-certified psychiatrist and psychotherapist with more than two decades of clinical experience, 25 years in research and development in many different indications across psychiatry, neurology, pain and rare CNS diseases. Dr Janikowski provides expert insights into design, implementation and analysis of neuroscience study data as we all as provides leaership and mentoring to Worldwide medical staff. Having served as a medical advisor to multiple clinical trials and worked with patients from adult and pediatric populations, he values patient’s and clinical site’s contribution to clinical investigations.
When we decide to do something, we do it well. Worldwide set out to improve psychiatric and neurologic health for patients around the world a long time ago. Now, our commitment to advancing the field through meaningful, standard-setting contributions is perhaps our greatest legacy.
Worldwide is one of the few full-service CROs that provides rater training, scale management, and management of electronic Clinical Outcome Assessments (eCOA/ePRO) vendors. We’ve conducted rater training and data surveillance for hundreds of domestic and international Phase I-IV trials and trained more than 7,000 raters.
Our founders and staff members have made substantial contributions to trial methodology in depression and psychiatric indications for the past 30+ years, authoring seminal citations and analyzing studies in all phases of development–meaning we can bring you an unparalleled understanding of the complexities of psychiatric trials to help mitigate risks inherent to this field.
A crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.
We’ve been a part of industry-sponsored psychedelic trials since they began. Our Psychedelic Center of Excellence has a comprehensive approach to the complex operational delivery of these trials and working with patients and sites for study success.
Worldwide was founded to help improve research for neurology patients. Decades later, we’ve done it all, working on a dizzying number of compounds and indications in every phase. Now Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and a broad range of other highly specialized consulting services in addition to our top-notch global network of study execution experts.
Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.
Rare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.
Worldwide leads the way in best practice development for pain and addiction research. We have seen it all, which helps us offer the right blend of tried-and-true logistics, creative study designs, and thoughtful outcomes measures to augment objectivity in this otherwise nebulous field of research.